Results 231 to 240 of about 732,598 (320)

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

Advanced Science, Volume 13, Issue 58, 19 October 2026.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong, Boyang Li, Jiahui Xu, Ruonan Lin, Jinghao Pan, Chenlu Fang, Boxiang Zhang, Lucy Yue Lau, Richard J. Aldridge, Elizabeth A. Whitmore, Yi Chen   +10 more
wiley   +1 more source

Enhancing IgG fragment crystallizable sialylation improves the therapeutic activity of IL-23 cytokine blockade. [PDF]

JCI Insight
Kämpf S, Hematianlarki M, Altmann L, Bright JM, Toda AM, Mirzapoor Z, Zollner V, Werner A, Bulang J, Radovani B, Wöhner M, Avery W, Karbarz MJ, Conley PB, Coffey GP, Nimmerjahn F.   +15 more
europepmc   +1 more source

Corynoxine Inhibits Tumor Growth via Targeting NQO1 and Modulating the PTPA–NQO1/PP2A Switch to Activate PP2A

Advanced Science, Volume 13, Issue 60, 28 October 2026.
Corynoxine exerts potent broad‐spectrum anticancer activity by directly targeting NQO1. This interaction dissociates the oncogenic NQO1‐PTPA complex, releasing PTPA to robustly activate the tumor suppressor PP2A. Consequently, downstream Raf/MEK/ERK and PI3K/AKT signaling pathways are suppressed, downregulating c‐Myc and driving tumor regression ...
Guoqing Hou, Li Lin, Mengjie Xia, Ruohan Liang, Yueyue Zhang, Linna Du, Xuan Cao   +6 more
wiley   +1 more source

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Yasuda M, Uzawa A, Handa H, Ogaya E, Kurumada K, Takasaka K, Mori M, Kuwabara S.   +7 more
europepmc   +1 more source

Transport–Reaction–Signal Coupling in Lateral Flow Assays for Next‐Generation Point‐of‐Care Diagnostics

Advanced Science, Volume 13, Issue 58, 19 October 2026.
Lateral flow assays are evolving into interdisciplinary, system‐level sensing platforms. Recent innovations are deconstructed through coupled phases of mass transfer, reaction, and signal transduction, revealing interdependence across porous materials, interfacial chemistry, nanolabels, readout devices, and data‐enabled analysis.
Yan Pan, Yuewei Li, Chao Mi, Zhengwen Yang, Lana McClements, Steven J. Langford, Jiayan Liao   +6 more
wiley   +1 more source

Trimeric autotransporter adhesins driving chain-like adhesion diversify surface colonization strategies in Shiga toxin-producing Escherichia coli. [PDF]

Nat Commun
Kotaka Y, Uemura NA, Iwase T, Lee K, Ishijima N, Nakane D, Kobayashi H, Kataoka M, Akeda Y, Iyoda S.   +9 more
europepmc   +1 more source

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

Morphological changes in peripheral blood of patients with type I and type II cryoglobulinemia. [PDF]

Pract Lab Med
Sun S, Wang G, Wang X, Fang Z, Wu W.
europepmc   +1 more source

Long Term Follow Up of Hereditary Thrombotic Thrombocytopenic Purpura on Plasma Therapy for 9 Years: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei, Chen Ruyue, Wu Shuang, Tang Hanyun, Lin Qiang, Li Xiaozhong   +5 more
wiley   +1 more source

Clinical outcomes and safety of efgartigimod in Guillain-Barré syndrome: a retrospective observation study. [PDF]

Front Immunol
Tao Y, Yang T, Jiang C, Wang X, Gu L, Zhang R.   +5 more
europepmc   +1 more source